ropinirole stada 2mg tableta s prodlouženým uvolňováním
stada arzneimittel ag, bad vilbel array - 14852 ropinirol-hydrochlorid - tableta s prodlouženým uvolňováním - 2mg - ropinirol
ropinirole stada 4mg tableta s prodlouženým uvolňováním
stada arzneimittel ag, bad vilbel array - 14852 ropinirol-hydrochlorid - tableta s prodlouženým uvolňováním - 4mg - ropinirol
ropinirole stada 8mg tableta s prodlouženým uvolňováním
stada arzneimittel ag, bad vilbel array - 14852 ropinirol-hydrochlorid - tableta s prodlouženým uvolňováním - 8mg - ropinirol
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - hydrochlorid klopidogrelu - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidla - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
atimos 12mcg/dáv roztok k inhalaci v tlakovém obalu
chiesi pharmaceuticals gmbh, vídeň array - 14188 dihydrÁt formoterol-fumarÁtu - roztok k inhalaci v tlakovém obalu - 12mcg/dÁv - formoterol
bisogamma 10 10mg potahovaná tableta
wörwag pharma gmbh & co. kg, böblingen nĚmecko - 10087 bisoprolol-fumarÁt - potahovaná tableta - 10mg - bisoprolol
bisogamma 5 5mg potahovaná tableta
wörwag pharma gmbh & co. kg, böblingen array - 10087 bisoprolol-fumarÁt - potahovaná tableta - 5mg - bisoprolol
budenofalk 2mg rektální pěna
dr. falk pharma gmbh, freiburg array - 5362 budesonid - rektální pěna - 2mg - budesonid
budenofalk uno 9mg enterosolventní granule
dr. falk pharma gmbh, freiburg array - 5362 budesonid - enterosolventní granule - 9mg - budesonid
bupropion +pharma 150mg tableta s řízeným uvolňováním
+pharma arzneimittel gmbh, graz array - 3813 bupropion-hydrochlorid - tableta s řízeným uvolňováním - 150mg - bupropion